Zydus Cadila seeks emergency-use nod from DCGI for its Covid-19 vaccine
Team Udayavani, Jul 1, 2021, 10:56 AM IST
Pharmaceutical major Zydus Cadila has applied for Emergency Use Authorisation (EUA) seeking DCGI’s approval for the launch of their ZyCoV-D vaccine for 12 years and above.
Sources said that the company has completed third phase clinical trials for the vaccine.
ZyCoV-D is the world’s first DNA vaccine against coronavirus and the fourth to become available in the country. The vaccine is a three-dose vaccine, with jabs to be administered at day 0, day 28, and day 56.
Notably this is the second indigenously developed vaccine after Bharat Biotech’s Covaxin.. The company has said it is also working on a two-dose regimen of this vaccine.
The stability data of the vaccine candidate showed that ZyCoV-D can be stored at 2 to 8 degrees Celsius for long-term use and 25 degrees Celsius for the short term.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Religious harmony threatened by Congress and supporters, claims Adityanath
Lok Sabha Polls 2024: Congress suspends Surat candidate Kumbhani, whose nomination form was rejected
Sibal criticizes EC for not issuing notice to Modi, terms it ‘powerless entity’
SC verdict on EVM a vindication of our faith in institutions: PM Modi in Bihar rallies
Shah: UCC Implementation in MP Fulfills BJP Pledge, Modi’s Commitment
MUST WATCH
Latest Additions
China says talks on Tibet only with Dalai Lama’s representatives; rules out dialogue on autonomy
Religious harmony threatened by Congress and supporters, claims Adityanath
Lok Sabha Polls 2024: Congress suspends Surat candidate Kumbhani, whose nomination form was rejected
Sibal criticizes EC for not issuing notice to Modi, terms it ‘powerless entity’
Yuvraj identifies Surya, Bumrah as key to India’s prospects in T20 World Cup